# MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

> **NCT04059523** · PHASE1 · COMPLETED · sponsor: **Sol-Gel Technologies, Ltd.** · enrollment: 62 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** S6G5T-3
- **DRUG:** Retin-A® 0.1% Cream

## Key facts

- **NCT ID:** NCT04059523
- **Lead sponsor:** Sol-Gel Technologies, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-02-06
- **Final completion:** 2020-02-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059523, "MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT04059523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*